Newly Diagnosed with Alzheimer’s? A Guide to Your Treatment Options, Risks and Costs
An early Alzheimer’s diagnosis brings important decisions. Learn about Leqembi, IQLIK, and Kisunla, including how they work, treatment schedules, ARIA risks, MRI monitoring, and Medicare costs. Use this guide to prepare for an informed discussion with your neurologist.
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK, the lecanemab autoinjector, is now available in the U.S. for initiation of treatment in people with early Alzheimer’s disease. This breakthrough adds a more convenient at-home option to the growing range of Alzheimer’s treatment choices and represents another important step forward in the fight against this devastating disease.
Leqembi IQLIK and Medicare: Everything You Need to Know Before You Switch
Should you stay on Leqembi infusions or switch to the new at-home IQLIK injection? That decision involves much more than convenience. Medicare covers the two treatments differently, and understanding Part B, Part D, specialty pharmacies, formularies, prior authorization, and the new annual out-of-pocket cap can save you both time and money. This practical guide explains the process step by step so people living with early Alzheimer's disease and their caregivers can make informed decisions before their first IQLIK prescription.